Efficacy and safety of immunotherapy for allergic rhinitis in the induction phase (Atena Editora)

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.contributor.authorALVAREZ-RIVERA, ARMANDO-
Autor(es): dc.contributor.authorCABALLERO-LÓPEZ, CHRYSTOPHERSON GENGYNY-
Autor(es): dc.contributor.authorLÓPEZ-GARCÍA, AIDA INÉS-
Autor(es): dc.contributor.authorRIVERO-YEVERINO, DANIELA-
Autor(es): dc.contributor.authorPAPAQUI-TAPIA, JOSÉ SERGIO-
Autor(es): dc.contributor.authorRIOS-LÓPEZ, JUAN JESÚS-
Autor(es): dc.contributor.authorJORDÁ-RODRÍGUEZ, ELISA ORTEGA-
Autor(es): dc.contributor.authorRUIZ-SÁNCHEZ, DULCE MARIEL-
Autor(es): dc.contributor.authorFLORES-GONZAGA, EDGAR-
Autor(es): dc.contributor.authorVILLADA-VILLADA, ERIKA-
Autor(es): dc.contributor.authorLÓPEZ-ROMERO, CARLOS DAVID-
Autor(es): dc.contributor.authorPAYAN-DÍAZ, JONATHAN HIGGINS-
Data de aceite: dc.date.accessioned2023-06-20T13:11:57Z-
Data de disponibilização: dc.date.available2023-06-20T13:11:57Z-
Data de envio: dc.date.issued2023-06-08-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/capes/731790-
Resumo: dc.description.abstractIntroduction.Allergen immunotherapy is an effective treatment for allergic rhinitis.Aim: to evaluate the efficacy and safety of subcutaneous immunotherapy during the induction phase according to the 2019 Mexican Immunotherapy Guide in patients with allergic rhinitis.Material and methods: analytical, prospective, quasi-experimental, longitudinal study in patients from 2 to 65 years of age with allergic rhinitis. Total Nasal Symptom Score and Portnoy were performed at the beginning and every two months, the data was analyzed with the IBM SPSS Statistics version 28 program. Summary and dispersion measures were used, comparing percentages by X2 and comparing means by variance ot Student test, considering a value of p <0.05 as statistically significant.Results:44 patients (22 women) were included, mean age 27.9 years. Mean symptom score before starting immunotherapy: 7.15, 4.04 at 2 months, 3.20 at 4 months and 2.77 at 6 months. Adverse effects occurred in 7.9% of the applications.Conclusions:The modifications stipulated for the induction phase in the 2019 Mexican Immunotherapy Guide are safe and effective in allergic rhinitis.pt_BR
Idioma: dc.language.isoenpt_BR
Palavras-chave: dc.subjectefficacypt_BR
Título: dc.titleEfficacy and safety of immunotherapy for allergic rhinitis in the induction phase (Atena Editora)pt_BR
Tipo de arquivo: dc.typelivro digitalpt_BR
Aparece nas coleções:Livros digitais